WO2011002168A3 - Use of novel lactobacillus helveticus or a culture thereof for preventing or treating dementia or cognitive dysfunction - Google Patents

Use of novel lactobacillus helveticus or a culture thereof for preventing or treating dementia or cognitive dysfunction Download PDF

Info

Publication number
WO2011002168A3
WO2011002168A3 PCT/KR2010/003972 KR2010003972W WO2011002168A3 WO 2011002168 A3 WO2011002168 A3 WO 2011002168A3 KR 2010003972 W KR2010003972 W KR 2010003972W WO 2011002168 A3 WO2011002168 A3 WO 2011002168A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
lactobacillus helveticus
culture
cognitive dysfunction
treating dementia
Prior art date
Application number
PCT/KR2010/003972
Other languages
French (fr)
Korean (ko)
Other versions
WO2011002168A2 (en
Inventor
최진성
유영상
김영재
양은희
권혁상
유정수
강병화
연승우
강재훈
Original Assignee
일동제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일동제약주식회사 filed Critical 일동제약주식회사
Publication of WO2011002168A2 publication Critical patent/WO2011002168A2/en
Publication of WO2011002168A3 publication Critical patent/WO2011002168A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to novel Lactobacillus helveticus, to a method for culturing same, and to the use thereof, and more particularly, to novel Lactobacillus helveticus which produces substances for inhibiting the production of amyloid-beta proteins, to pharmaceutical compositions containing the culture of Lactobacillus helveticus as an active ingredient for preventing or treating dementia or cognitive dysfunction, to the use thereof, to a method for preventing or treating dementia or cognitive dysfunction, and to a method for culturing same. The Lactobacillus helveticus or the culture thereof according to the present invention is effective in preventing or treating dementia, and in improving cognitive function or in preventing or treating cognitive dysfunction.
PCT/KR2010/003972 2009-06-30 2010-06-18 Use of novel lactobacillus helveticus or a culture thereof for preventing or treating dementia or cognitive dysfunction WO2011002168A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0059051 2009-06-30
KR1020090059051A KR101087973B1 (en) 2009-06-30 2009-06-30 Novel Lactobacillus helveticus, culture method thereof and use thereof

Publications (2)

Publication Number Publication Date
WO2011002168A2 WO2011002168A2 (en) 2011-01-06
WO2011002168A3 true WO2011002168A3 (en) 2011-05-19

Family

ID=43411556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003972 WO2011002168A2 (en) 2009-06-30 2010-06-18 Use of novel lactobacillus helveticus or a culture thereof for preventing or treating dementia or cognitive dysfunction

Country Status (2)

Country Link
KR (1) KR101087973B1 (en)
WO (1) WO2011002168A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110793A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF PROBIOTIC BACTERIA AND SYNBIOTIC COMPOSITION CONTAINING THEMSELVES INTENDED FOR THE BABY FOOD.
KR101799830B1 (en) 2016-06-14 2017-11-21 한국생명공학연구원 Agathobaculum sp. strain for preventing or treating degenerative brain disease and uses thereof
IT201700057079A1 (en) * 2017-05-25 2018-11-25 Probiotical Spa Bacteriotherapy based on bacterial compositions for the treatment of neurodegenerative diseases
KR102250597B1 (en) * 2017-11-20 2021-05-11 경희대학교 산학협력단 Novel lactic acid bacteria and use thereof
AU2021229110B2 (en) * 2020-02-26 2024-05-23 Gi Biome Lactobacillus Helveticus strain and composition containing same for prevention or treatment of inflammatory diseases
CN112715949A (en) * 2020-12-22 2021-04-30 军事科学院军事医学研究院环境医学与作业医学研究所 Application of lactobacillus plantarum LP45 in preparation of functional food for improving cognitive impairment caused by high altitude hypoxia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284243B1 (en) * 1995-07-14 2001-09-04 Calpis Co., Ltd. Physiologically functional food having brain function-improving, learning ability-enhancing, and memory-enhancing functions
US20030235559A1 (en) * 2002-06-21 2003-12-25 Sobol Constantin Vladimirovich Composition and method for producing and use of a fermented hydrolyzed medium containing microorganisms and products of their metabolism
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US20040057943A1 (en) * 2002-06-28 2004-03-25 Jordi Xaus Pey Probiotic strains, a process for the selection of them, compositions thereof, and their use
WO2006126682A1 (en) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vaccine for prevention/treatment of alzheimer disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284243B1 (en) * 1995-07-14 2001-09-04 Calpis Co., Ltd. Physiologically functional food having brain function-improving, learning ability-enhancing, and memory-enhancing functions
US20030235559A1 (en) * 2002-06-21 2003-12-25 Sobol Constantin Vladimirovich Composition and method for producing and use of a fermented hydrolyzed medium containing microorganisms and products of their metabolism
US20040057943A1 (en) * 2002-06-28 2004-03-25 Jordi Xaus Pey Probiotic strains, a process for the selection of them, compositions thereof, and their use
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
WO2006126682A1 (en) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vaccine for prevention/treatment of alzheimer disease

Also Published As

Publication number Publication date
WO2011002168A2 (en) 2011-01-06
KR101087973B1 (en) 2011-12-01
KR20110001493A (en) 2011-01-06

Similar Documents

Publication Publication Date Title
WO2013075116A3 (en) Omega 7 rich compositions and methods of isolating omega 7 fatty acids
EP2488652A4 (en) Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-coa, putrescine and related compounds, and methods related thereto
WO2011002168A3 (en) Use of novel lactobacillus helveticus or a culture thereof for preventing or treating dementia or cognitive dysfunction
MX2014007255A (en) Processes and compositions for increasing the digestibility of cellulosic materials.
EP3466960A3 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
EP3409666A3 (en) Seca inhibitors and methods of making and using thereof
SG176656A1 (en) Microorganisms for the production of 1,4-butanediol and related methods
EP2345667A3 (en) A method for producing an L-amino acid using a bacterium of the enterobacteriaceae family
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2010139719A3 (en) Biocatalytic production of ambroxan
WO2011163500A3 (en) Methods and compositions for reducing body odor
MX2013011625A (en) Flavor-enhancing lactobacillus rhamnosus.
WO2010114982A3 (en) Lyophilization cakes of proteasome inhibitors
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
MX2012004780A (en) Akt inhibitors.
WO2009089263A3 (en) Novel compositions and methods of use
AP2492A (en) Novel compositions of fungal inocula, method for the preparation thereof and use thereof for improving the growth of cultures
EP2652141A4 (en) Microorganisms and methods for the production of 1.4- cyclohexanedimethanol
WO2014206419A3 (en) Compositions comprising fermented seaweed and/or algae
EP2583969A4 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
WO2012087670A3 (en) Genetically engineered microorganisms comprising 4-hydroxybenzoyl-coa thioesterases and methods of using the same
WO2011050270A3 (en) Macrocyclic inhibitors of serine protease enzymes
WO2011057006A3 (en) Insecticidal fermentation broth from actinomycetes
WO2010098583A3 (en) Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10794303

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10794303

Country of ref document: EP

Kind code of ref document: A2